142 related articles for article (PubMed ID: 36939263)
1. Symptom Assessment of Patients with Allergic Rhinitis Using an Allergen Exposure Chamber.
Zemelka-Wiacek M; Kosowska A; Jutel M
J Vis Exp; 2023 Mar; (193):. PubMed ID: 36939263
[TBL] [Abstract][Full Text] [Related]
2. Validated allergen exposure chamber is plausible tool for the assessment of house dust mite-triggered allergic rhinitis.
Zemelka-Wiacek M; Kosowska A; Winiarska E; Sobanska E; Jutel M
Allergy; 2023 Jan; 78(1):168-177. PubMed ID: 35980665
[TBL] [Abstract][Full Text] [Related]
3. Clinical validation of grass pollen exposure chamber in patients with allergic rhinitis triggered by timothy grass.
Kosowska A; Zemelka-Wiącek M; Smolińska S; Wyrodek E; Adamczak B; Jutel M
Clin Exp Allergy; 2024 Apr; ():. PubMed ID: 38616622
[TBL] [Abstract][Full Text] [Related]
4. [Efficacy comparison and safety analysis of subcutaneous specific immunotherapy with standardized house dust mite allergen in patients with single and multiple allergic rhinitis].
Huang HH; Xu C; Liu L; Chai RN
Zhonghua Yu Fang Yi Xue Za Zhi; 2022 Jun; 56(6):774-783. PubMed ID: 35785859
[No Abstract] [Full Text] [Related]
5. The effect of immunotherapy on cross-reactivity between house dust mite and other allergens in house dust mite -sensitized patients with allergic rhinitis.
Zhao L; Zhang Y; Zhang S; Zhang L; Lan F
Expert Rev Clin Immunol; 2021 Sep; 17(9):969-975. PubMed ID: 34388949
[TBL] [Abstract][Full Text] [Related]
6. Safety, efficacy and repeatability of a novel house dust mite allergen challenge technique in the Fraunhofer allergen challenge chamber.
Lueer K; Biller H; Casper A; Windt H; Mueller M; Badorrek P; Haefner D; Framke T; Koch A; Ziehr H; Krug N; Koch W; Hohlfeld JM
Allergy; 2016 Dec; 71(12):1693-1700. PubMed ID: 27255590
[TBL] [Abstract][Full Text] [Related]
7. Sodium Chloride versus Lactose as a Carrier for House Dust Mite Allergen in Allergen Chamber Studies: A Clinical Study to Assess Noninferiority.
Struß N; Dieter S; Schwarz K; Badorrek P; Hohlfeld JM
Int Arch Allergy Immunol; 2023; 184(11):1143-1152. PubMed ID: 37586347
[TBL] [Abstract][Full Text] [Related]
8. Onset and dose-related efficacy of house dust mite sublingual immunotherapy tablets in an environmental exposure chamber.
Nolte H; Maloney J; Nelson HS; Bernstein DI; Lu S; Li Z; Kaur A; Zieglmayer P; Zieglmayer R; Lemell P; Horak F
J Allergy Clin Immunol; 2015 Jun; 135(6):1494-501.e6. PubMed ID: 25636947
[TBL] [Abstract][Full Text] [Related]
9. Assessing the efficacy of a novel temperature and humidity control machine to minimize house dust mite allergen exposure and clinical symptoms in allergic rhinitis children sensitized to dust mites: a pilot study.
Manuyakorn W; Padungpak S; Luecha O; Kamchaisatian W; Sasisakulporn C; Vilaiyuk S; Monyakul V; Benjaponpitak S
Asian Pac J Allergy Immunol; 2015 Jun; 33(2):129-35. PubMed ID: 26141034
[TBL] [Abstract][Full Text] [Related]
10. Sublingual immunotherapy in children with allergic rhinoconjunctivitis mono-sensitized to house-dust-mites: a double-blind-placebo-controlled randomised trial.
Aydogan M; Eifan AO; Keles S; Akkoc T; Nursoy MA; Bahceciler NN; Barlan IB
Respir Med; 2013 Sep; 107(9):1322-9. PubMed ID: 23886432
[TBL] [Abstract][Full Text] [Related]
11. Peak nasal inspiratory flow as outcome for provocation studies in allergen exposure chambers: a GA
Boelke G; Berger U; Bergmann KC; Bindslev-Jensen C; Bousquet J; Gildemeister J; Jutel M; Pfaar O; Sehlinger T; Zuberbier T
Clin Transl Allergy; 2017; 7():33. PubMed ID: 28932387
[TBL] [Abstract][Full Text] [Related]
12. Clinical validation of controlled exposure to house dust mite in the environmental exposure unit (EEU).
Hossenbaccus L; Linton S; Thiele J; Steacy L; Walker T; Malone C; Ellis AK
Allergy Asthma Clin Immunol; 2021 Mar; 17(1):34. PubMed ID: 33771217
[TBL] [Abstract][Full Text] [Related]
13. Barrier-forming, drug-free nasal spray reduces allergic symptoms induced by house dust mite allergen.
Couroux P; Grosse N; Salapatek AM; Goyal Y; Pfaar O; Hohenfeld IP
Clin Transl Allergy; 2023 Jul; 13(7):e12277. PubMed ID: 37488728
[TBL] [Abstract][Full Text] [Related]
14. Effective treatment of house dust mite-induced allergic rhinitis with 2 doses of the SQ HDM SLIT-tablet: Results from a randomized, double-blind, placebo-controlled phase III trial.
Demoly P; Emminger W; Rehm D; Backer V; Tommerup L; Kleine-Tebbe J
J Allergy Clin Immunol; 2016 Feb; 137(2):444-451.e8. PubMed ID: 26292778
[TBL] [Abstract][Full Text] [Related]
15. Nasal IgE in subjects with allergic and non-allergic rhinitis.
Eckrich J; Hinkel J; Fischl A; Herrmann E; Holtappels G; Bachert C; Zielen S
World Allergy Organ J; 2020 Jun; 13(6):100129. PubMed ID: 32612737
[TBL] [Abstract][Full Text] [Related]
16. Technical and clinical validation of the Allergen BioCube
Angjeli E; Gomes P; Lane KJ; Stein L; Abelson MB
Immun Inflamm Dis; 2017 Mar; 5(1):78-84. PubMed ID: 28250927
[TBL] [Abstract][Full Text] [Related]
17. House dust mite allergen immunotherapy for monosensitized versus polysensitized patients with allergic rhinitis: A systematic review and meta-analysis.
Phinyo P; Krikeerati T; Wongyikul P; Lao-Araya M; Thongngarm T
Asian Pac J Allergy Immunol; 2022 Dec; 40(4):337-352. PubMed ID: 36278778
[TBL] [Abstract][Full Text] [Related]
18. Utility of silver birch and house dust mite extracts derived from licensed sublingual tablets for nasal allergen challenge.
Olivieri B; Gil AJ; Stoenchev K; Durham SR; Scadding G
Clin Transl Allergy; 2024 May; 14(5):e12360. PubMed ID: 38779783
[TBL] [Abstract][Full Text] [Related]
19. Efficacy of subcutaneous house dust mite immunotherapy in patients with moderate to severe allergic rhinitis.
Valero A; Ibáñez-Echevarría E; Vidal C; Raducan I; Castelló Carrascosa JV; Sánchez-López J
Immunotherapy; 2022 Jun; 14(9):683-694. PubMed ID: 35465692
[TBL] [Abstract][Full Text] [Related]
20. [Rhinitis in adults].
Kalogjera L
Acta Med Croatica; 2011; 65(2):181-7. PubMed ID: 22359885
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
